Inhibition of IL-1β by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial

Journal: Cancer Research

Published: 2020-12-15

DOI: 10.1158/0008-5472.can-19-3176

Affiliations: 4

Authors: 14

Go to article
Institutions Share
Novartis Pharmaceuticals Corporation, United States of America (USA) 0.64
Novartis Institutes for Biomedical Research (NIBR), United States of America (USA) 0.21
IQVIA, United States of America (USA) 0.07
Brigham and Women's Hospital (BWH), United States of America (USA) 0.07

Return